Research Article
PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement
Table 1
Clinical-pathological characteristics of breast cancers involved in this study.
| | Factors | Total case study 305 (100%) | LN- 151 (49.5%) | LN+ 154 (50.5%) |
| | Age (years) | | | | | ≤35 | 21 (6.9%) | 4 (2.6%) | 17 (11.0%) | | >35 | 284 (93.1%) | 147 (97.4%) | 137 (89.0%) | | Mean age (years) (range) | 46.9 (26-55) | 46.8 (32-55) | 47.0 (26-55) | | Histology | | | | | Ductal | 259 (84.9%) | 118 (78.1%) | 141 (91.6%) | | Lobular | 16 (5.2%) | 9 (6.0%) | 7 (4.5%) | | Medullary | 8 (2.6%) | 8 (5.3) | — | | Mucinous | 4 (1.3%) | 3 (2.0%) | 1 (0.6%) | | Tubular | 7 (2.3%) | 7 (4.6%) | — | | Others | 11 (3.6%) | 6 (4.0%) | 5 (3.2%) | | Grade | | | | | 1 | 39 (12.8%) | 33 (21.9%) | 6 (3.9%) | | 2 | 144 (47.2%) | 86 (57%) | 58 (37.7%) | | 3 | 119 (39.0%) | 31 (20.5%) | 88 (57.1%) | | Unknown | 3 (1.0%) | 1 (0.7%) | 2 (1.3%) | | Tumor size (cm) | | | | | ≤2 | 179 (58.7%) | 107 (70.9%) | 72 (46.8%) | | 2-5 | 100 (32.8%) | 35 (23.2%) | 65 (42.2%) | | ≥5 | 13 (4.3%) | 1 (0.7%) | 12 (7.8%) | | Unknown | 13 (4.3%) | 8 (5.3%) | 5 (3.2%) | | Lymph nodes | | | | | 1-3 lymph nodes | 90 (29.5%) | — | 90 (58.4%) | | ≥4 lymph nodes | 45 (14.8%) | — | 45 (29.2%) | | Unknown | 19 (6.2%) | | 19 (12.3%) | | Stage | | | | | I | 107 (35.1%) | 107 (70.9%) | — | | II | 125 (41.0%) | 42 (27.8%) | 83 (53.9%) | | III | 72 (23.6%) | 2 (1.3%) | 70 (45.5%) | | Unknown | 1 (0.3%) | — | 1 (0.6%) | | Recurrence | | | | | No | 143 (46.9%) | 98 (64.9%) | 45 (29.2%) | | Yes | 147 (48.2%) | 49 (32.5%) | 98 (63.6%) | | Unknown | 15 (4.9%) | 4 (2.6%) | 11 (7.1%) | | ER | | | | | Negative | 63 (20.7%) | 25 (16.6%) | 38 (24.7%) | | Positive | 242 (79.3%) | 126 (83.4%) | 116 (75.3%) | | PR | | | | | Negative | 81 (26.6%) | 27 (17.9%) | 54 (35.1%) | | Positive | 223 (73.1%) | 123 (81.5%) | 100 (64.9%) | | Unknown | 1 (0.3%) | 1 (0.7%) | — | | ERBB-2 | | | | | Negative | 242 (79.3%) | 139 (92.0%) | 103 (66.9%) | | Positive | 61 (20.0%) | 11 (7.3%) | 50 (32.5%) | | Unknown | 2 (0.7%) | 1 (0.7%) | 1(0.6%) | | Ki67 | | | | | <20% | 172 (56.4%) | 108 (71.5%) | 64 (41.6%) | | ≥20% | 133 (43.6%) | 43 (28.5%) | 90 (58.4%) | | KRT8 | | | | | Negative | 28 (9.2%) | 12 (7.9%) | 16 (10.4%) | | Positive | 263 (86.2%) | 134 (88.7%) | 129 (83.8%) | | Unknown | 14 (4.6%) | 5 (3.3%) | 9 (5.8%) | | KRT5/6 | | | | | Negative | 230 (75.4%) | 107 (70.9%) | 123 (79.9%) | | Positive | 70 (23.0%) | 42 (27.8%) | 28 (18.2%) | | Unknown | 5 (1.6%) | 2 (1.3%) | 3 (1.9%) | | Vimentin | | | | | Negative | 216 (70.8%) | 97 (64.2%) | 119 (77.3%) | | Positive | 60 (19.7%) | 42 (27.8%) | 18 (11.7%) | | Unknown | 29 (9.5%) | 12 (7.9%) | 17 (11.0%) |
|
|
